Adverse Cardiovascular Events in Cancer Trials: Missing in Action?

Affiliations

¹ MedStar Heart and Vascular Institute, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC. Electronic address: nhb20@georgetown.edu.
² Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.

Free article

Editorial

Nanette H Bishopric et al. J Am Coll Cardiol. 2020.

Free article

. 2020 Feb 18;75(6):629-631.

doi: 10.1016/j.jacc.2019.12.019.

¹ MedStar Heart and Vascular Institute, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC. Electronic address: nhb20@georgetown.edu.
² Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.

No abstract available

Keywords: U.S. Food and Drug Administration; cancer clinical trials; cardio-oncology; cardiovascular disease; reporting of adverse events.

Comment on

Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies.
Bonsu JM, Guha A, Charles L, Yildiz VO, Wei L, Baker B, Brammer JE, Awan F, Lustberg M, Reinbolt R, Miller ED, Jneid H, Ruz P, Carter RR, Milks MW, Paskett ED, Addison D. Bonsu JM, et al. J Am Coll Cardiol. 2020 Feb 18;75(6):620-628. doi: 10.1016/j.jacc.2019.11.059. J Am Coll Cardiol. 2020. PMID: 32057377 Free PMC article.